Table 4 Factors potentially associated with 10-day mortality according to characteristics evaluated and results of bivariate and multivariate tests in 161 episodes of bacteremia caused by Streptococcus pneumoniae in cancer patients.

Sex

0.034

 Female

1

 Male

2.155 (1.05–4.42)

 Age (years)

1.007 (0.98–1.04)

0.643**

Ethnicity

0.159^#

 Asian

&

 White

1.118 (0.46–2.72)

 Black

0.739 (0.23–2.38)

 Mixed

1

Comorbidities

 Systemic arterial hypertension

0.785 (0.41–1.52)

0.471

 Diabetes mellitus

0.37 (0.14–1.52)

0.036

 Congestive heart failure

0.373 (0.08–1.77)

0.340*

 COPD

0.878 (0.46–1.69)

0.698

 Smoking

0.754 (0.39–1.45)

0.399

 Splenectomy

&

 > 0.999*

 AIDS/HIV

1.2 (0.28–5.22)

 > 0.999*

 Neoplasm

0.056#

Solid tumors

 Head and neck^a

1

 GTI

1.079 (0.4–2.93)

 Respiratory tract

0.517 (0.16–1.71)

 Liver/bile ducts

0.295 (0.05–1.69)

 Breasts

0.591 (0.09–3.86)

 Pancreas

1.182 (0.14–9.83)

 Female genitourinary

0.394 (0.04 -4.35)

 Bones/cartilage/SST

0.394 (0.04–4.35)

 Male genitourinary

&

 Timo/parotid

&

 Hematologic neoplasms

 Multiple myeloma

0.131 (0.03–0.70)

 Non-Hodgkin's lymphoma

0.197 (0.04–1.08)

 Hodgkin's lymphoma

0.394 (0.04–0.82)

 Leukemias

&

Karnofsky

0.053

 90/100

1

 < 90

2.014 (0.98–4.12)

ECOG

0.032

 0/1/2

1

0.937

 3/4

2.25 (1.06–4.77)/5.93 (2.04–17.22) ***

0.937/0.001***

 Presence of metastases

2.218 (1.11–4.41)

0.022

 Radiotherapy past month

1.354 (0.58–3.14)

0.479

 Chemotherapy past month

0.941 (0.49–1.83)

0.858

 Monoclonal antibodies past month

6.235 (0.63–61.43)

0.110*

 Corticotherapy past month

1.331 (0.66–2.67)

0.421

 Community-acquired infection

1.029 (0.51–2.06)

0.72

 Health-care infection

0.972 (0.49–1.95)

0.72

Primary site infection

0.018^#

 Lung

1

 Abdomen

0.372 (0.10–1.37)

 Bloodstream infection

&

 Central nervous system

&

 Oropharynx/facial sinuses

&

 SST

1.612 (0.1–26.37)

 Biliary ducts

&

 Urinary tract

&

 Fever in the 48 h preceding the episode

0.42 (0.21–0.82)/0.351 (0.14–0.88)***

0.01/(0.026)***

Neutropenia

 Neutropenia past month

3.227 (1.56–6.67)

0.001

 Current neutropenia

3.91 (1.83–8.36)/4.006 (1.38–11.65)***

 < 0.001/0.011***

 Severe neutropenia past month

3.369 (1.59–7.16)

0.001

 Current severe neutropenia

3.908 (1.78–8.59)

 < 0.001

 Prolonged neutropenia past month

1.347 (0.36–4.99)

0.733*

 Febrile neutropenia 48 h preceding the episode

2.359 (1.05–5.29)

0.034

 Antibiotics last month

0.81 (0.40–1.67)

0.571

 SOFA

1.4 (1.24–1.60)/1.407 (1.2–1.66)***

 < 0.001£/ < 0.001***

 Strain susceptibility

&

0.335*

 MIC PEN

1.16 (0.62–2.19)

0.904£

 MIC CRO

1.31 (0.27–6.23)

0.369£

 PEN susceptibility (MIC ≤ 2)

&

0.333*

 CRO susceptibility (MIC ≤ 1)

&

&

 CLI susceptibility

1.089 (0.32–3.73)

 > 0.999*

 CHL susceptibility

&

0.329*

 ERY susceptibility

1.98 (0.62–6.31)

0.241

 LEV susceptibility

&

&

 SXT susceptibility

1.345 (0.68–2.68)

0.398

 TET susceptibility

2.017 (0.76–5.35)

0.153

 VAN susceptibility

&

&

Vaccination

 Vaccine serotype VCV 13^b

2.72 (1.21–6.14)

0.014

 Vaccine serotype VPV 23^c

0.915 (0.38–2.2)

0.842

 Pneumococcal vaccine before the episode

&

0.539*

 Pneumococcal vaccine in any time

&

&

 Antimicrobial treatment

 Instituted in the first 24 h

0.359 (0.13–0.97)

0.038

 3rd and 4th generation cephalosporin

0.331 (0.16–0.67)

0.002

 Penicilins^d

1.708 (0.87–63.36)

0.119

 Fluoroquinolones^e

0.053 (0.01–0.40)/0.083 (0.01–0.71)***

 < 0.001/0.023***

 Glycopeptide/linezolid

1.454 (0.75–2.81)

0.266

 SMX/TMP

&

 > 0.999*

 Clindamycin

0.777 (0.15–4.14)

 > 0.999*

 Polymicrobial bacteremia

3.395 (1.39–8.28)

0.005